TABLE 2.
Characteristics of leprosy cases with antimicrobial resistance from October 2018 to September 2020 in Brazila
| No. | Case | Resistanceb | Genotype | Region | Age | Sex | Clinical form, WHO | BI | Treatment | Reaction | Relapse data |
Suspected treatment failure data |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time of relapse (yrs) | Previous treatment/no. doses | Outcome of previous treatment | Entry/yr | Current treatment/no. doses | |||||||||||
| 1 | Relapse | Rifampin + dapsone | rpoB TCG 456 TTG (Ser-Leu) folP1 CCC 55 CGC (Pro-Arg) | Southeast | 61 | F | MB | NA | Substitutive | NA | NA | MDT-MB irregular/9 | Abandonment | ||
| 2 | Relapse | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | Southeast | 53 | F | MB | 0.0 | MDT | No | 7 | MDT-PB regular/6 | Cure | ||
| 3 | Relapse | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | North | 28 | F | MB | 4.0 | MDT | Yes | NA | MDT-MB irregular/8 | Abandonment | ||
| 4 | Relapse | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | Midwest | 42 | M | MB | NA | MDT | No | 12 | MDT-MB regular/12 | Cure | ||
| 5 | Relapse | Dapsone | folP1 ACC 53 GCC (Thr-Ala) | South | 80 | M | MB | NA | MDT | No | 6 | MDT-MB regular/24 | Cure | ||
| 6 | Relapse | Rifampin | rpoB TCG 456 ATG (Ser-Met) | Southeast | 24 | M | MB | 2.75 | MDT | No | 9 | MDT-PB irregular/6 | Cure | ||
| 7 | Relapse | Dapsone | folP1 ACC 53 ATC (Tre-Ile) | North | 80 | F | MB | 4.0 | MDT | NA | NA | NA | NA | ||
| 8 | Relapse | Ofloxacin | gyrA GCA 91 GTA (Ala-Val) | North | 37 | M | MB | 3.25 | MDT | Yes | NA | MDT-MB irregular/12 | Cure | ||
| 9 | Suspected treatment failure | Rifampin + dapsone | rpoB TCG 456 TTG (Ser-Leu) folP1 CCC 55 CGC (Pro-Arg) | Southeast | 36 | M | MB | NA | MDT | No | New case/2018 | MDT-MB/17 | |||
| 10 | Suspected treatment failure | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | Midwest | 51 | F | MB | NA | MDT | No | New case/2018 | MDT-MB/17 | |||
| 11 | Suspected treatment failure | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | Midwest | 28 | M | MB | NA | MDT | Yes | Reentry/2019 | MDT-MB/15 | |||
| 12 | Suspected treatment failure | Dapsone | folP1 ACC 53 GCC (Thr-Ala) | Midwest | 51 | M | MB | 1.0 | Substitutive | Yes | New case/2015 | MDT-MB/24 | |||
| 13 | Suspected treatment failure | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | North | 75 | F | MB | 4.0 | MDT | No | Reentry/2019 | MDT-MB/17 | |||
| 14 | Suspected treatment failure | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | North | 24 | F | MB | 4.0 | Substitutive | No | New case/2017 | MDT-MB/NA | |||
| 15 | Suspected treatment failure | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | North | 44 | F | MB | 3.3 | MDT | Yes | New case/2017 | MDT-MB/NA | |||
| 16 | New case | Dapsone | folP1 CCC 55 CGC (Pro-Arg) | Southeast | 59 | M | MB | 2.0 | MDT | Yes | |||||
a
M, male; F, female; WHO, World Health Organization; MB, multibacillary; BI, bacilloscopic index; NA, not available; MDT, multidrug therapy; substitutive, treatment regimen with ofloxacin, minocycline, and clarithromycin.
b
Resistance inferred from mutations in drug resistance-determining regions that have been proven to cause resistance.